Valeant Pharmaceuticals International Inc
Score: Positive (87)
8 days at current score.
Upgraded from Neutral on June 26th 2018
- This company ranked positively compared to the Healthcare sector despite only 2 positive IHS Markit Categories
- Perception of the company's creditworthiness is positive
- Bearish sentiment is low
Short interest | Positive
Short interest is extremely low for VRX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRX.
ETF/Index ownership | Neutral
ETF activity is neutral. ETFs that hold VRX had net inflows of $2.15 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing.
PMI by IHS Markit | Neutral
According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is very weak relative to the trend shown over the past year. In fact, it has been weak enough that the rate of expansion may accelerate in the coming months.
Credit default swap | Positive
The current level displays a positive indicator. VRX credit default swap spreads are near the lowest level of the last three years and indicate the market's continued positive perception of the company's credit worthiness.
Please send all inquiries related to the report to email@example.com.
Charts and report PDFs will only be available for 30 days after publishing.
This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.